Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors.
about
Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma modelMagnetic resonance perfusion imaging in neuro-oncology.Antagonism of peripheral inflammation reduces the severity of status epilepticus.Methodology of brain perfusion imaging.Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data.Use of 99m-technetium-glucoheptonate as a tracer for brain tumor imaging: An overview of its strengths and pitfalls.Advanced magnetic resonance imaging techniques to evaluate CNS glioma.A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR.Response criteria for glioma.Effects of postnatal dexamethasone on blood-brain barrier permeability and brain water content in newborn lambs.MRI for identification of progression in brain tumors: from morphology to function.Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy.Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain.Conventional MRI evaluation of gliomas.Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics.MRI for assessing antivascular cancer treatments.Non Tumor Perfusion Changes Following Stereotactic Radiosurgery to Brain MetastasesExclusion of a brain lesion: is intravenous contrast administration required after normal precontrast magnetic resonance imaging?MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administrationDiagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue NecrosisAssessing the neuroendocrine stress response in the functional neuroimaging contextDynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.Emerging insights into barriers to effective brain tumor therapeutics.Brain metastases: an overview.Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.[ (11) C]-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomas.Assessment of Glioma Response to Radiotherapy Using Multiple MRI Biomarkers with Manual and Semiautomated Segmentation Algorithms.Quantitative rapid steady state T1 magnetic resonance imaging for cerebral blood volume mapping in mice: Lengthened measurement time window with intraperitoneal Gd-DOTA injection.Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas.Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brImaging diagnosis--lack of contrast enhancement in metastatic cerebral adenocarcinoma.Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas.
P2860
Q28742242-C235F10B-A45E-405D-BE64-57B1F939E9A7Q30479156-D6D4922C-02EF-4BCA-8B45-E67F055FCB1EQ30498265-487DF6BB-E2E0-489A-B8A7-33532639B395Q30643023-23C8A02A-2248-4037-B899-86AD06366A45Q30770588-24556BA7-0FA5-4847-B530-6EFFD54F0803Q30884478-14A69AD0-2AE6-4D9F-B8DA-05EAE319D19EQ31016364-06C565AA-71E8-4E8E-A3E5-C0E3D8C3269DQ31113091-6DDE04C4-7859-48A9-9E4C-C345B7668FCFQ31172444-608F80F6-3FB5-42B5-A294-C8BD8BA13599Q32031812-F25A19CD-AEBF-4C22-8013-143CB8E7DFE8Q33377547-64D8FAC1-9DBC-46D6-8CDC-3D4FF2952432Q33742612-339E11C4-E08B-44D8-B074-0EBD583871B2Q33966638-0869E5BE-9642-40A5-872D-E3CDDEBE2E80Q34203916-76F898C5-66A1-47C6-8796-5F3A7EB4F90FQ34203930-6A89BA17-C5E8-42EE-B9C2-E6C132540032Q34918635-54846859-4115-47AB-913A-0B058827127AQ35078406-47BAADD3-D184-4FD6-9691-96CE58EE289CQ35627742-8DB5DC39-C25F-423C-B81E-EF98D40003F2Q35800552-64EB06B5-C203-4A29-B6BE-0AFC0E33256EQ35863183-E1FE732C-083C-445D-85CA-1704F475495AQ35894329-A129CC00-E97D-4DC9-9104-126E3DC325D7Q35905005-254E5230-490B-4D69-B514-EC0A7AC4B6FAQ36266287-0917D902-B3D4-4AD6-A85C-3064FCDAA793Q36873251-A5664725-39D2-4DBB-A601-2A3F8D2BF1A3Q36955458-111A0373-6310-43E5-AEC0-DB8CFC8A740BQ37016981-6EF30CDF-A815-4BAA-AF38-15A318BC875FQ37312878-C6F340BF-A26E-42D6-80E4-54A7330030F3Q37354846-5504BEE8-D1BF-41A0-B5AE-43E86CFF8E3CQ37469178-65453C65-68CA-48CF-B821-CF367C20579FQ38237653-1CD5C1DD-1A85-44D9-A808-DD1DC4DFAABEQ38317417-18792655-4738-4208-810D-F13EDFD3DFD5Q38674490-CD85BE72-84EA-4FF6-997E-F53BF2F2828AQ41871381-A3EEE0A6-1958-4672-B1C6-B5BC8412217EQ42679323-5C074D43-742A-4C94-A203-DF49510744D7Q44839200-F35CDD63-75BB-4A21-B14E-17AD2D36B7D8Q45267961-E2B04E57-9692-49A7-90DB-E87256C58DD4Q45858439-ED5CCEBF-B30B-46B3-818E-C2EC6DAEA632Q48130398-2B4AAF55-ED3F-48FB-A64E-15356A153EE9Q48460317-FAFC963B-2325-4161-A91A-31962FF219CCQ48586633-D5FB0EAA-612B-4008-95CF-1293BA77225C
P2860
Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Early changes measured by magn ...... in patients with brain tumors.
@ast
Early changes measured by magn ...... in patients with brain tumors.
@en
type
label
Early changes measured by magn ...... in patients with brain tumors.
@ast
Early changes measured by magn ...... in patients with brain tumors.
@en
prefLabel
Early changes measured by magn ...... in patients with brain tumors.
@ast
Early changes measured by magn ...... in patients with brain tumors.
@en
P2093
P921
P1476
Early changes measured by magn ...... in patients with brain tumors.
@en
P2093
Gonzalez RG
Gyldensted C
Hochberg FH
Rabinov JD
Sorensen AG
Weisskoff RM
P304
P356
10.3171/JNS.1999.90.2.0300
P577
1999-02-01T00:00:00Z